Educate, Test and Treat Model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.
Egypt has one of the highest burdens of HCV infection worldwide, and a large treatment programme, but reaching rural communities represents a major challenge. We report the feasibility and effectiveness of a comprehensive community-based HCV prevention, testing and treatment model in 73 villages across Egypt, with the goal to eliminate infection from all adult villagers. An HCV "educate, test and treat" programme was implemented in 73 villages across 7 governorates in Egypt between 06/2015 and 06/2018. The programme model comprised community mobilization facilitated by a network of village promoters to support the education, test and treat campaign as well as fund raising in the local community; a comprehensive testing, linkage to care and treatment of all eligible villagers aged 12 to 80 years using HCV antibody and HBsAg rapid diagnostic tests (RDTs), HCV RNA confirmation of positive cases, staging of liver disease using transient elastography (FibroScan) or FIB4 score, treatment with 12 or 24 weeks of a direct acting antiviral (DAA) regimen, and an assessment of cure at 12 weeks after completion of treatment (SVR12); and an education campaign to raise awareness and disseminate messages about safer practices to reduce transmission through public events, promotional materials and house-to-house visits. Key outcomes assessed in each village were: uptake of serological HCV and HBV testing, HCV viral load confirmation and treatment, and SVR12. 204749 (92.3%, 95% CI 91.6-93.5) of 221855 eligible villagers were screened for HCV antibody and HBsAg, and 33839 (16.5%, 95% CI 12.2-16.1) and 763 (0.4%, 95% CI 0.3-0.5) were positive, respectively. Nearly all 33839 HCV antibody positive individuals had immediate sample collected for HCV RNA and 15892 (47.0%, 95% CI 44.8-53.8) were positive. Overall, prevalence of HCV viremia was 7.8%, 95% CI 6.6-7.9. 14495 (91.2%, 95% CI 89.9-96.4) received treatment within a median of 2.1 weeks from serological diagnosis (IQR: 0.6 to 3.3 weeks). SVR12) was achieved among 14238 of the treated cases (98.3%, 95% CI 96.7-98.6). 3192 (20.1%) had cirrhosis, and of these 166 (5.2%) were diagnosed with HCC. This large community-based educate, test and treat programme in more than 200,000 villagers demonstrates the feasibility and effectiveness of this model for elimination of HCV infection in rural communities. We estimate treatment coverage and cure of 84.6% of the estimated 17137 infected persons aged 12-80 years across the 73 villages.